The Korean journal of internal medicine

  • 제39권3호
  • /
  • Pages.524-536
  • /
  • 2024
  • /
  • 1226-3303(pISSN)
  • /
  • 2005-6648(eISSN)
대한내과학회 (The Korean Association of Internal Medicine)
권호 표지
DOI QR코드

DOI QR Code

Overlap syndrome of systemic sclerosis with antineutrophil cytoplasmic antibody-associated vasculitis according to 2022 ACR/EULAR criteria

  • Jang Woo Ha (Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Jung Yoon Pyo (Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Sung Soo Ahn (Department of Internal Medicine, Yongin Severance Hospital, Yonsei University College of Medicine) ;
  • Jason Jungsik Song (Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Yong-Beom Park (Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine) ;
  • Sang-Won Lee (Division of Rheumatology, Department of Internal Medicine, Yonsei University College of Medicine)
  • 투고 : 2023.07.05
  • 심사 : 2023.09.09
  • 발행 : 2024.05.01
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background/Aims: This study applied the 2022 American College of Rheumatology (ACR)/European Alliance of Associations for Rheumatology (EULAR) criteria for antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) to patients with systemic sclerosis (SSc) and investigated the frequency of overlap syndrome of SSc and AAV (SSc-AAV-OS). Methods: Among the 232 patients diagnosed with SSc, 105 with signs suggestive of small- or medium-vessel vasculitis, which were defined as the present of interstitial lung disease (ILD), peripheral neuropathy, or suspected renal vasculitis, were included in this study and analyzed. Results: Among the 105 SSc patients, the detection rate of ANCA was 19.0%. When the 2022 ACR/EULAR criteria were applied, the frequency of SSc-AAV-OS was 20.0%, which was much higher than 1.7% reported with previous criteria for AAV. ANCA positivity contributed to the reclassification of SSc-AAV-OS more than ANCA negativity in SSc patients with signs suggestive of small- or medium-vessel vasculitis. Conclusions: The frequency of SSc-AAV-OS in SSc patients with signs suggestive of small- or medium-vessel vasculitis at diagnosis was 20.0%. Therefore, we suggest that physicians should perform ANCA tests in SSc patients exhibiting signs suggestive of small- or medium-vessel vasculitis and apply the new criteria for AAV.

키워드

과제정보

This study received funding from the Korea Health Technology R&D Project through the Korea Health Industry Development Institute, funded by the Ministry of Health and Welfare (HI14C1324), Handok Inc., Seoul, Republic of Korea (HANDOK 2021-006), and from CELLTRION PHARM, Inc. Chungcheongbuk-do, Republic of Korea (NCR 2019-6).

참고문헌

  1. Denton CP, Khanna D. Systemic sclerosis. Lancet 2017;390:1685-1699.  https://doi.org/10.1016/S0140-6736(17)30933-9
  2. Jennette JC, Falk RJ, Bacon PA, et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013;65:1-11.  https://doi.org/10.1002/art.37715
  3. Watts R, Lane S, Hanslik T, et al. Development and validation of a consensus methodology for the classification of the ANCA-associated vasculitides and polyarteritis nodosa for epidemiological studies. Ann Rheum Dis 2007;66:222-227.  https://doi.org/10.1136/ard.2006.054593
  4. Kant S, Shah AA, Hummers LK, Wigley FM, Geetha D. ANCA-associated vasculitis in scleroderma: a renal perspective . Clin Nephrol 2018;90:413-418.  https://doi.org/10.5414/CN109445
  5. Wu R, Su J, Zou YR, Zhu J. ANCA-associated vasculitis overlaps with systemic sclerosis: a case report and literature review. Eur J Med Res 2021;26:30. 
  6. Moxey J, Huq M, Proudman S, et al. Significance of anti-neutrophil cytoplasmic antibodies in systemic sclerosis. Arthritis Res Ther 2019;21:57. 
  7. Radwan Y, Berini S, Ernste F, Makol A. Proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA)-associated vasculitic neuropathy in diffuse cutaneous systemic sclerosis: a rare duo. BMJ Case Rep 2019;12:e232987. 
  8. Ha JW, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Significance of antineutrophil cytoplasmic antibody positivity in patients with systemic sclerosis: a single-centre pilot study in Korea. Clin Exp Rheumatol 2021;39 Suppl 131:111-118.  https://doi.org/10.55563/clinexprheumatol/nkcry1
  9. Suppiah R, Robson JC, Grayson PC, et al.; DCVAS INVESTIGATORS. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis. Ann Rheum Dis 2022;81:321-326.  https://doi.org/10.1136/annrheumdis-2021-221796
  10. Robson JC, Grayson PC, Ponte C, et al.; DCVAS Investigators. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for granulomatosis with polyangiitis. Ann Rheum Dis 2022;81:315-320.  https://doi.org/10.1136/annrheumdis-2021-221795
  11. Grayson PC, Ponte C, Suppiah R, et al.; DCVAS Study Group. 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for eosinophilic granulomatosis with polyangiitis. Ann Rheum Dis 2022;81:309-314.  https://doi.org/10.1136/annrheumdis-2021-221794
  12. van den Hoogen F, Khanna D, Fransen J, et al. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis 2013;72:1747-1755.  https://doi.org/10.1136/annrheumdis-2013-204424
  13. Do H, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Cancer-associated vasculitides: a single-centre case series. Clin Rheumatol 2023;42:151-158.  https://doi.org/10.1007/s10067-022-06363-0
  14. Phatak S, Aggarwal A, Agarwal V, Lawrence A, Misra R. Antineutrophil cytoplasmic antibody (ANCA) testing: audit from a clinical immunology laboratory. Int J Rheum Dis 2017;20:774-778.  https://doi.org/10.1111/1756-185X.12926
  15. Lee WI, Subramaniam K, Hawkins CA, Randall KL. The significance of ANCA positivity in patients with inflammatory bowel disease. Pathology 2019;51:634-639.  https://doi.org/10.1016/j.pathol.2019.07.002
  16. Wong AH, Wong WK, Looi LM, Ratnasingam J, Lim SK. Propylthiouracil-induced antineutrophil cytoplasmic antibodies-associated vasculitis with renal and lung involvement. Case Rep Nephrol Dial 2022;12:105-111.  https://doi.org/10.1159/000525182
  17. Alawneh D, Edrees A. Hydralazine-induced antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis: a case report and literature review. Cureus 2022;14:e24132. 
  18. Bossuyt X, Cohen Tervaert JW, Arimura Y, et al. Position paper: revised 2017 international consensus on testing of ANCAs in granulomatosis with polyangiitis and microscopic polyangiitis. Nat Rev Rheumatol 2017;13:683-692.  https://doi.org/10.1038/nrrheum.2017.140
  19. Choi CB, Park YB, Lee SW. Antineutrophil cytoplasmic antibody-associated vasculitis in Korea: a narrative review. Yonsei Med J 2019;60:10-21.  https://doi.org/10.3349/ymj.2019.60.1.10
  20. Kitching AR, Anders HJ, Basu N, et al. ANCA-associated vasculitis. Nat Rev Dis Primers 2020;6:71. 
  21. Quemeneur T, Mouthon L, Cacoub P, et al. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine (Baltimore) 2013;92:1-9.  https://doi.org/10.1097/MD.0b013e31827781fd
  22. Asano Y, Sato S. Vasculopathy in scleroderma. Semin Immunopathol 2015;37:489-500.  https://doi.org/10.1007/s00281-015-0505-5
  23. Ha JW, Pyo JY, Ahn SS, Song JJ, Park YB, Lee SW. Incidence and patterns of interstitial lung disease and their clinical impact on mortality in patients with antineutrophil cytoplasmic antibody-associated vasculitis: Korean single-centre observational study. J Immunol Res 2022;2022:2499404. 
  24. Ha JW, Hong YJ, Cha HJ, et al. A retrospective analysis of the relationship between anti-cyclic citrullinated peptide antibody and interstitial lung disease in systemic sclerosis. Sci Rep 2022;12:19253.